Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.54
SUPN's Cash-to-Debt is ranked higher than
89% of the 886 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. SUPN: 1.54 )
Ranked among companies with meaningful Cash-to-Debt only.
SUPN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 2.76 Max: No Debt
Current: 1.54
0.19
No Debt
Equity-to-Asset 0.43
SUPN's Equity-to-Asset is ranked lower than
52% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SUPN: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
SUPN' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.48 Max: 0.68
Current: 0.43
-2.25
0.68
Debt-to-Equity 0.90
SUPN's Debt-to-Equity is ranked lower than
99.99% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. SUPN: 0.90 )
Ranked among companies with meaningful Debt-to-Equity only.
SUPN' s Debt-to-Equity Range Over the Past 10 Years
Min: -12.18  Med: 0.12 Max: 106.19
Current: 0.9
-12.18
106.19
Debt-to-EBITDA 2.51
SUPN's Debt-to-EBITDA is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SUPN: 2.51 )
Ranked among companies with meaningful Debt-to-EBITDA only.
SUPN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7  Med: -0.55 Max: 14.4
Current: 2.51
-7
14.4
Interest Coverage 58.93
SUPN's Interest Coverage is ranked lower than
54% of the 683 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 132.39 vs. SUPN: 58.93 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 4.37  Med: 10.65 Max: 63.48
Current: 58.93
4.37
63.48
Piotroski F-Score: 5
Altman Z-Score: 5.13
Beneish M-Score: -2.75
WACC vs ROIC
13.50%
51.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 34.06
SUPN's Operating Margin % is ranked higher than
94% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.96 vs. SUPN: 34.06 )
Ranked among companies with meaningful Operating Margin % only.
SUPN' s Operating Margin % Range Over the Past 10 Years
Min: -37851.89  Med: -148.31 Max: 34.06
Current: 34.06
-37851.89
34.06
Net Margin % 21.89
SUPN's Net Margin % is ranked higher than
85% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. SUPN: 21.89 )
Ranked among companies with meaningful Net Margin % only.
SUPN' s Net Margin % Range Over the Past 10 Years
Min: -36285.85  Med: -5.29 Max: 6701.74
Current: 21.89
-36285.85
6701.74
ROE % 28.07
SUPN's ROE % is ranked higher than
90% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.75 vs. SUPN: 28.07 )
Ranked among companies with meaningful ROE % only.
SUPN' s ROE % Range Over the Past 10 Years
Min: -202.72  Med: -3.9 Max: 65.21
Current: 28.07
-202.72
65.21
ROA % 15.92
SUPN's ROA % is ranked higher than
91% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.29 vs. SUPN: 15.92 )
Ranked among companies with meaningful ROA % only.
SUPN' s ROA % Range Over the Past 10 Years
Min: -90.03  Med: -4.12 Max: 106.84
Current: 15.92
-90.03
106.84
ROC (Joel Greenblatt) % 2476.17
SUPN's ROC (Joel Greenblatt) % is ranked higher than
100% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.64 vs. SUPN: 2476.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SUPN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4247.75  Med: -987.47 Max: 2476.17
Current: 2476.17
-4247.75
2476.17
3-Year Revenue Growth Rate 37.30
SUPN's 3-Year Revenue Growth Rate is ranked higher than
95% of the 681 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SUPN: 37.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SUPN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.65 Max: 235.6
Current: 37.3
0
235.6
GuruFocus has detected 3 Warning Signs with Supernus Pharmaceuticals Inc SUPN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SUPN's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

SUPN Guru Trades in Q2 2017

Ron Baron 44,602 sh (New)
Chuck Royce 159,000 sh (+22.31%)
Jeremy Grantham 8,200 sh (unchged)
Paul Tudor Jones Sold Out
Robert Bruce 34,581 sh (-46.45%)
Joel Greenblatt 24,381 sh (-76.10%)
» More
Q3 2017

SUPN Guru Trades in Q3 2017

Joel Greenblatt 168,536 sh (+591.26%)
Robert Bruce 178,058 sh (+414.90%)
Ron Baron 89,621 sh (+100.93%)
Jeremy Grantham 8,200 sh (unchged)
Chuck Royce 159,000 sh (unchged)
» More
Q4 2017

SUPN Guru Trades in Q4 2017

Jim Simons 26,100 sh (New)
Robert Bruce 178,058 sh (unchged)
Jeremy Grantham Sold Out
Joel Greenblatt 139,597 sh (-17.17%)
Ron Baron 66,561 sh (-25.73%)
Chuck Royce 99,000 sh (-37.74%)
» More
Q1 2018

SUPN Guru Trades in Q1 2018

John Hussman 50,000 sh (New)
Jim Simons 303,700 sh (+1063.60%)
Robert Bruce 178,058 sh (unchged)
Ron Baron Sold Out
Chuck Royce 67,000 sh (-32.32%)
Joel Greenblatt 32,781 sh (-76.52%)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2018-03-31 Reduce -76.52%0.06%$37.15 - $46.9 $ 58.0539%32,781
Ron Baron 2018-03-31 Sold Out 0.01%$37.15 - $46.9 $ 58.0539%0
Joel Greenblatt 2017-12-31 Reduce -17.17%0.02%$36.4 - $42.6 $ 58.0547%139,597
Ron Baron 2017-12-31 Reduce -25.73%0.01%$36.4 - $42.6 $ 58.0547%66,561
Robert Bruce 2017-09-30 Add 414.90%1.41%$36.75 - $49.65 $ 58.0534%178,058
Joel Greenblatt 2017-09-30 Add 591.26%0.09%$36.75 - $49.65 $ 58.0534%168,536
Ron Baron 2017-09-30 Add 100.93%0.01%$36.75 - $49.65 $ 58.0534%89,621
Ron Baron 2017-06-30 New Buy0.01%$30.15 - $44.15 $ 58.0564%44,602
Robert Bruce 2017-06-30 Reduce -46.45%0.25%$30.15 - $44.15 $ 58.0564%34,581
Joel Greenblatt 2017-06-30 Reduce -76.10%0.03%$30.15 - $44.15 $ 58.0564%24,381
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:BOM:532296, XTER:EVT, TSE:4521, SZSE:300199, SZSE:000078, SHSE:600277, SHSE:600267, SZSE:002907, SHSE:603707, NAS:HZNP, SZSE:002390, HKSE:00460, XLJU:KRKG, SHSE:600216, NAS:MDCO, NAS:HRTX, TSE:4540, SHSE:600380, NAS:IRWD, SHSE:603367 » details
Traded in other countries:S49.Germany,
Headquarter Location:USA
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Ratios

vs
industry
vs
history
PE Ratio 42.90
SUPN's PE Ratio is ranked lower than
70% of the 584 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. SUPN: 42.90 )
Ranked among companies with meaningful PE Ratio only.
SUPN' s PE Ratio Range Over the Past 10 Years
Min: 0.5  Med: 36.93 Max: 235.67
Current: 42.9
0.5
235.67
Forward PE Ratio 31.15
SUPN's Forward PE Ratio is ranked lower than
61% of the 111 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.00 vs. SUPN: 31.15 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.90
SUPN's PE Ratio without NRI is ranked lower than
69% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.44 vs. SUPN: 42.90 )
Ranked among companies with meaningful PE Ratio without NRI only.
SUPN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.74  Med: 36.93 Max: 235.67
Current: 42.9
0.74
235.67
Price-to-Owner-Earnings 25.81
SUPN's Price-to-Owner-Earnings is ranked higher than
70% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.72 vs. SUPN: 25.81 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SUPN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.56  Med: 21.94 Max: 179.75
Current: 25.81
9.56
179.75
PB Ratio 8.57
SUPN's PB Ratio is ranked lower than
85% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. SUPN: 8.57 )
Ranked among companies with meaningful PB Ratio only.
SUPN' s PB Ratio Range Over the Past 10 Years
Min: 3.23  Med: 7.56 Max: 18.53
Current: 8.57
3.23
18.53
PS Ratio 9.33
SUPN's PS Ratio is ranked lower than
75% of the 784 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.25 vs. SUPN: 9.33 )
Ranked among companies with meaningful PS Ratio only.
SUPN' s PS Ratio Range Over the Past 10 Years
Min: 3.77  Med: 7.32 Max: 617.62
Current: 9.33
3.77
617.62
Price-to-Free-Cash-Flow 24.71
SUPN's Price-to-Free-Cash-Flow is ranked higher than
56% of the 216 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.03 vs. SUPN: 24.71 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SUPN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.26  Med: 21.96 Max: 82.21
Current: 24.71
15.26
82.21
Price-to-Operating-Cash-Flow 24.32
SUPN's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.21 vs. SUPN: 24.32 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SUPN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.72  Med: 21.49 Max: 76.29
Current: 24.32
14.72
76.29
EV-to-EBIT 24.25
SUPN's EV-to-EBIT is ranked lower than
55% of the 599 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.78 vs. SUPN: 24.25 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -72.8  Med: 19.3 Max: 96
Current: 24.25
-72.8
96
EV-to-EBITDA 22.51
SUPN's EV-to-EBITDA is ranked lower than
58% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.59 vs. SUPN: 22.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -90.8  Med: 17.95 Max: 88.7
Current: 22.51
-90.8
88.7
EV-to-Revenue 8.52
SUPN's EV-to-Revenue is ranked lower than
72% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. SUPN: 8.52 )
Ranked among companies with meaningful EV-to-Revenue only.
SUPN' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.3  Med: 7.2 Max: 652.7
Current: 8.52
3.3
652.7
Current Ratio 4.90
SUPN's Current Ratio is ranked lower than
64% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. SUPN: 4.90 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.83 Max: 8.39
Current: 4.9
1.51
8.39
Quick Ratio 4.74
SUPN's Quick Ratio is ranked lower than
57% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.02 vs. SUPN: 4.74 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.63 Max: 8.39
Current: 4.74
1.49
8.39
Days Inventory 404.40
SUPN's Days Inventory is ranked lower than
96% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.78 vs. SUPN: 404.40 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 397.09  Med: 563.95 Max: 1372.72
Current: 404.4
397.09
1372.72
Days Sales Outstanding 73.92
SUPN's Days Sales Outstanding is ranked lower than
54% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.10 vs. SUPN: 73.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 70.5 Max: 153.48
Current: 73.92
2.71
153.48
Days Payable 78.26
SUPN's Days Payable is ranked higher than
84% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. SUPN: 78.26 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 78.26  Med: 186.94 Max: 1038.8
Current: 78.26
78.26
1038.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.10
SUPN's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SUPN: -6.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SUPN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.8  Med: -3.05 Max: 0
Current: -6.1
-45.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 181.41
SUPN's Price-to-Net-Cash is ranked lower than
99.99% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.33 vs. SUPN: 181.41 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SUPN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.22  Med: 29.97 Max: 1403
Current: 181.41
4.22
1403
Price-to-Net-Current-Asset-Value 27.25
SUPN's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.09 vs. SUPN: 27.25 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SUPN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.98  Med: 27.23 Max: 122.18
Current: 27.25
3.98
122.18
Price-to-Tangible-Book 9.44
SUPN's Price-to-Tangible-Book is ranked lower than
82% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. SUPN: 9.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SUPN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.86  Med: 8.43 Max: 19.49
Current: 9.44
3.86
19.49
Price-to-Intrinsic-Value-Projected-FCF 5.52
SUPN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
71% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.58 vs. SUPN: 5.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SUPN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.36  Med: 11.43 Max: 37.71
Current: 5.52
4.36
37.71
Price-to-Median-PS-Value 1.27
SUPN's Price-to-Median-PS-Value is ranked higher than
50% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. SUPN: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SUPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.99 Max: 77
Current: 1.27
0.52
77
Price-to-Graham-Number 4.23
SUPN's Price-to-Graham-Number is ranked lower than
84% of the 425 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. SUPN: 4.23 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SUPN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.75  Med: 3.69 Max: 8.71
Current: 4.23
0.75
8.71
Earnings Yield (Greenblatt) % 4.13
SUPN's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 888 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. SUPN: 4.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SUPN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -105.6  Med: 1.65 Max: 6
Current: 4.13
-105.6
6

More Statistics

Revenue (TTM) (Mil) $335.09
EPS (TTM) $ 1.36
Beta1.75
Volatility37.08%
52-Week Range $33.30 - 59.05
Shares Outstanding (Mil)51.80

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 1.77 2.46
EPS without NRI ($) 1.77 2.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}